BLASINGLE-USEVIALPriority Review
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Mechanism of Action
interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β and prevents its interaction with cell surface receptors. Rilonacept also binds interleukin-1 receptor antagonist…
Clinical Trials (5)
Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Started Jan 2019
86 enrolled
Recurrent Pericarditis
Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss
Started Feb 2017
10 enrolled
Autoimmune Neurosensory Hearing Loss (ANSHL)
Cold Contact Urticaria Treatment With Rilonacept
Started Jan 2015
20 enrolled
Cold Contact Urticaria
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Started Dec 2011
24 enrolled
SclerodermaSystemic SclerosisDiffuse Scleroderma+1 more
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Started Nov 2011
220 enrolled
Gout